Narrative Review of Advancements in Stem Cell Therapy: Adipose-Derived Stem Cells for Diabetic Foot Ulcer Treatment
Abstract
Diabetic foot ulcers (DFUs) are a severe complication of diabetes, with current standard care often failing to prevent chronic morbidity and amputation. This narrative review examines the therapeutic potential of adipose-derived stem cells (ADSCs) for DFUs treatment. ADSCs promote healing through paracrine secretion of growth factors, immunomodulation, and stimulation of angiogenesis, as demonstrated in promising preclinical and early clinical studies. We outline these mechanisms, discuss the emerging role of ADSC-derived exosomes as a potentially safer alternative, and summarize key clinical findings. However, significant challenges remain, including potential risks of tumorigenicity, donor cell variability, and a lack of standardized protocols. While ADSC therapy represents a highly promising regenerative approach for DFUs, its safety and efficacy must be firmly established through more rigorous preclinical studies and large-scale, randomized controlled trials before it can be broadly adopted in clinical practice. This review concludes that while ADSC therapy is a highly promising regenerative approach for DFUs, its translation to clinical practice necessitates further rigorous investigations to overcome existing translational barriers.
2. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376(24):2367-75.
3. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet. 2005;366(9498):1736-43.
4. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001;7(2):211-28.
5. Vizoso FJ, Eiro N, Cid S, et al. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18(9):1852.
6. Fang J, Chen F, Liu D, et al. Adipose tissue-derived stem cells in breast reconstruction: a brief review on biology and translation. Stem Cell Res Ther. 2021;12(1):8.
7. Bura A, Planat-Benard V, Bourin P, et al. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy. 2014;16(2):245-57.
8. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc. 2000;5(1):40-6.
9. Yoshimura K, Shigeura T, Matsumoto D, et al. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. J Cell Physiol. 2006;208(1):64-76.
10. Park N, Kim KS, Park CG, et al. Adipose-derived stem cell-based anti-inflammatory paracrine factor regulation for the treatment of inflammatory bowel disease. J Control Release. 2024;374:384-99.
11. Burgess JL, Wyant WA, Abdo Abujamra B, et al. Diabetic wound-healing science. Medicina (Kaunas). 2021;57(10):1072.
12. Deng H, Chen Y. The role of adipose-derived stem cells-derived extracellular vesicles in the treatment of diabetic foot ulcer: trends and prospects. Front Endocrinol (Lausanne). 2022;13:902130.
13. Papadopoulos KS, Piperi C, Korkolopoulou P. Clinical applications of adipose-derived stem cell (ADSC) exosomes in tissue regeneration. Int J Mol Sci. 2024;25(11):5916.
14. Gu Y, Mu Z, Chen Y, et al. Therapeutic potential of ADSCs in diabetic wounds: a proteomics-based approach. Front Cell Dev Biol. 2024;12:1468220.
15. Zhang J, Liu Y, Chen Y, et al. Adipose-derived stem cells: current applications and future directions in the regeneration of multiple tissues. Stem Cells Int. 2020; 2020: 8810813.
16. Tseng S, Kang L, Li Z, et al. Adipose-derived stem cells in diabetic foot care: bridging clinical trials and practical application. World J Diabetes. 2024;15(6):1162-77.
17. Kumar R, Mohammadnezhad M, Khan S. Perception of Type 2 Diabetes Mellitus (T2DM) patients on diabetes self-care management in Fiji. PLoS One. 2024;19(5):e0304708.
18. Zhou YL, Ogura S, Ma H, et al. Adipose-derived stem cells extracellular vesicles enhance diabetic wound healing via CCN2/PI3K/AKT pathway: therapeutic potential and mechanistic insights. Stem Cell Res Ther. 2025;16(1):304.
19. Ganesan O, Orgill DP. An overview of recent clinical trials for diabetic foot ulcer therapies. J Clin Med. 2024;13(24):7655.
20. Farres H. Adipose-derived stromal cells (ASC's) for pressure ulcers ClinicalTrials.gov identifier: NCT02375802. Rochester: Mayo Clinic; 2014 Available from: https://clinicaltrials.gov/ct2/show/NCT02375802
21. Mrozikiewicz-Rakowska B, Szabłowska-Gadomska I, Cysewski D, et al. Allogenic adipose-derived stem cells in diabetic foot ulcer treatment: clinical effectiveness, safety, survival in the wound site, and proteomic impact. Int J Mol Sci. 2023;24(2):1472.
22. Yastı AÇ, Akgun AE, Surel AA, et al. Graft of 3D bioprinted autologous minimally manipulated homologous adipose tissue for the treatment of diabetic foot ulcer. Wounds. 2023;35(1):E22-E28.
23. Bajuri MY, Kim J, Yu Y, et al. New paradigm in diabetic foot ulcer grafting techniques using 3D-bioprinted autologous minimally manipulated homologous adipose tissue (3D-AMHAT) with fibrin gel acting as a biodegradable scaffold. Gels. 2023;9(1):66.
24. Kress GT, Swerdlow M, Mohan N, et al. Remission strategies with fat grafting to prevent recurrence of pedal ulcerations and pain: a case series. Plast Reconstr Surg Glob Open. 2023;11(9):e5232.
25. Nolan GS, Smith OJ, Heavey S, et al. Histological analysis of fat grafting with platelet-rich plasma for diabetic foot ulcers-A randomised controlled trial. Int Wound J. 2022;19(2):389-98.
26. Uzun E, Güney A, Gönen ZB, et al. Intralesional allogeneic adipose-derived stem cells application in chronic diabetic foot ulcer: Phase I/2 safety study. Foot Ankle Surg. 2021;27(6):636-42.
27. Carstens MH, Quintana FJ, Calderwood ST, et al. Treatment of chronic diabetic foot ulcers with adipose-derived stromal vascular fraction cell injections: Safety and evidence of efficacy at 1 year. Stem Cells Transl Med. 2021;10(8):1138-47.
28. Gennai S, Leone N, Covic T, et al. Health-related quality of life outcomes and hospitalization length of stay after micro-fragmented autologous adipose tissue injection in minor amputations for diabetic foot ulceration (MiFrAADiF Trial): results from a randomized controlled single-center clinical trial. Int Angiol. 2021;40(6):512-9.
29. Nilforoushzadeh MA, Sisakht MM, Amirkhani MA, et al. Engineered skin graft with stromal vascular fraction cells encapsulated in fibrin-collagen hydrogel: A clinical study for diabetic wound healing. J Tissue Eng Regen Med. 2020;14(3):424-440.
30. Smith OJ, Leigh R, Kanapathy M, et al. Fat grafting and platelet-rich plasma for the treatment of diabetic foot ulcers: A feasibility-randomised controlled trial. Int Wound J. 2020;17(6):1578-94.
31. Moon KC, Suh HS, Kim KB, et al. Potential of allogeneic adipose-derived stem cell-hydrogel complex for treating diabetic foot ulcers. Diabetes. 2019;68(4):837-46.
32. Lonardi R, Leone N, Gennai S, et al. Autologous micro-fragmented adipose tissue for the treatment of diabetic foot minor amputations: a randomized controlled single-center clinical trial (MiFrAADiF). Stem Cell Res Ther. 2019;10(1):223.
33. Raposio E, Bertozzi N, Grignaffini E, et al. Adipose-derived stem cells for treatment of chronic cutaneous ulcers in patients with critical limb ischemia: a pilot study. J Regen Med. 2016;5:1: 1000128.
34. Dreifuss SE, Minteer DT, Gusenoff B, et al. Abstract: Autologous pedal fat grafting: A randomized cross-over clinical trial: Autologous pedal fat grafting. Plast Reconstr Surg Glob Open. 2017;5(9 Suppl):99-100.
35. Zhang X, Kuang Q, Xu J, et al. MSC-based cell therapy in neurological diseases: a concise review of the literature in pre-clinical and clinical research. Biomolecules. 2024;14(5):538.
36. Pu LLQ, Coleman SR, Cui X, et al. Autologous fat grafts harvested and refined by Coleman technique: A comparative study. Plast Reconstr Surg. 2008;122(3):932-937.
37. Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. Vasc Endovascular Surg. 2005;39(4):293-306.
38. Gan F, Liu L, Zhou Q, et al. Effects of adipose-derived stromal cells and endothelial progenitor cells on adipose transplant survival and angiogenesis. PLoS One. 2022;17(1):e0261498.
39. Chamberlain RC, Fleetwood K, Wild SH, et al. Foot ulcer and risk of lower limb amputation or death in people with diabetes: a national population-based retrospective cohort study. Diabetes Care. 2022;45(1):83-91.
40. Feng H, Gong S, Liu J, et al. Adipose-derived stem cell exosomes: mechanisms and therapeutic potentials in wound healing. Biomark Res. 2025;13(1):88.
41. Zhang Z, Yu K, You Y, et al. Comprehensive characterization of human brain-derived extracellular vesicles using multiple isolation methods: Implications for diagnostic and therapeutic applications. J Extracell Vesicles. 2023;12(8):e12358.
42. Yi J, Tang Q, Sun S, et al. Exosomes in diabetic wound healing: mechanisms, applications, and perspectives. Diabetes Metab Syndr Obes. 2025;18:2955-76.
43. Wang Y, Ding H, Bai R, et al. Exosomes from adipose-derived stem cells accelerate wound healing by increasing the release of IL-33 from macrophages. Stem Cell Res Ther. 2025;16(1):80.
44. Takakura Y, Hanayama R, Akiyoshi K, et al. Quality and safety considerations for therapeutic products based on extracellular vesicles. Pharm Res. 2024;41(8):1573-94.
45. Baldursson BT, Kjartansson H, Konrádsdóttir F, et al. Healing rate and autoimmune safety of full-thickness wounds treated with fish skin acellular dermal matrix versus porcine small-intestine submucosa: a noninferiority study. Int J Low Extrem Wounds. 2015;14(1):37-43.
46. Liu R, Dong R, Chang M, et al. Adipose-derived stem cells for the treatment of diabetic wound: From basic study to clinical application. Front Endocrinol (Lausanne). 2022;13:882469.
47. Mikłosz A, Nikitiuk BE, Chabowski A. Using adipose-derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand? Obes Rev. 2022;23(5):e13413.
48. Muehlberg FL, Song YH, Krohn A, et al. Tissue-resident stem cells promote growth of metastatic tumors in the brain. J Clin Invest. 2009;119(8):2313-22.
49. Bernardo ME, Zaffaroni N, Novara F, et al. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67(19):9142-9.
50. Alt EU, Senst C, Murthy SN, et al. Aging alters tissue resident mesenchymal stem cell properties. Stem Cell Res. 2012;8(2):215-25.
51. Han F, Wang J, Ding L, et al. Tissue engineering and regenerative medicine: achievements, future, and sustainability in Asia. Front Bioeng Biotechnol. 2020;8:83.
52. Shi YY, Nacamuli RP, Salim A, et al. The osteogenic potential of adipose-derived mesenchymal cells is maintained with aging. Plast Reconstr Surg. 2005;116(6):1686-96.
53. Kim WS, Park BS, Sung JH. Wound healing effect of adipose-derived stem cells: a critical role of secretory factors on human dermal fibroblasts. J Dermatol Sci. 2007;48(1):15-24.
54. Yu Q, Qiao GH, Wang M, et al. Stem cell-based therapy for diabetic foot ulcers. Front Cell Dev Biol. 2022;10:812262.
55. Gentile P, Scioli MG, Bielli A, et al. Concise review: the use of adipose-derived stromal vascular fraction cells and platelet rich plasma in regenerative plastic surgery. Stem Cells. 2017;35(1):117-34.
56. Liu J, Ren J, Su L, et al. Human adipose tissue-derived stem cells inhibit the activity of keloid fibroblasts and fibrosis in a keloid model by paracrine signaling. Burns. 2018;44(2):370-85.
57. Lee HC, An SG, Lee HW, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J. 2012;76(7):1750-60.
58. Lee AS, Tang C, Rao MS, et al. Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med. 2013;19(8):998-1004.
59. Zhu M, Heydarkhan-Hagvall S, Hedrick M, et al. Manual isolation of adipose-derived stem cells from human lipoaspirates. J Vis Exp. 2013;(79):e50585.
60. Zhang Y, Yu M, Tian W. Physiological and pathological impact of exosomes of adipose tissue. Cell Prolif. 2016;49(1):3-13.
61. Rani S, Ryan AE, Griffin MD, et al. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. Mol Ther. 2015;23(5):812-23.
62. Lötvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913.
63. Patel JC, Shukla M, Shukla M. From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence. Front Bioeng Biotechnol. 2025;13:1639439.
64. Monaghan TF, Agudelo CW, Rahman SN, et al. Blinding in clinical trials: seeing the big picture. Medicina (Kaunas). 2021;57(7):647.
Files | ||
Issue | Vol 19 No 4 (2025) | |
Section | Review Article(s) | |
Keywords | ||
Diabetes; Adipose; Stem cell; Healing, Ulcer; Therapy |
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |